Lung Cancer
While ALRN-6924 is first being tested in breast and lung cancer, the firm believes it can help patients with any type of p53-mutated cancer avoid chemo toxicities.
The firm's next move will be to pit aumolertinib against AstraZeneca's Tagrisso, the new standard of care in EGFR-mutated NSCLC.
Bayer Cancels Cell Therapy Licensing Deal With Atara Biotherapeutics
Bayer has notified Atara of plans to terminate its exclusive worldwide licensing deal for the mesothelin-directed cell therapies ATA3271 and ATA2271.
City of Hope, Imugene Begin Trial of Oncolytic Virus in Advanced Solid Cancers
The partners will see if the oncolytic virus CF33-hNIS, dubbed Vaxinia, can increase PD-L1 tumor expression and make patients responsive to Merck's Keytruda.
Qiagen Gets CE Mark for Therascreen EGFR Plus RGQ Kit for Non-Small Cell Lung Cancer
The firm has launched the in vitro diagnostic test, which detects EGFR mutations in non-small cell lung cancer, in 11 countries that accept the CE mark.